27552486|t|Effectiveness of the Consecutive Alternating Administration Course of a Triple Antiviral Combination in Coxsackievirus B3 Infections in Mice
27552486|a|Anti-enteroviral chemotherapeutics for clinical use are not registered so far, mainly due to the rapid development of drug-resistance. One of the possible approaches to overcome this problem is the use of combined chemotherapy. However, its application consisting of simultaneously given drugs, is not efficacious because of the development of multiple resistance. Here we present a novel approach for combined application of anti-enteroviral compounds, consisting of a consecutive alternating administration (CAA) course. CAA was tested on 2 in vivo models of Coxsackievirus B3 infection in newborn mice at inoculation dose of 20 MLD50 (50% mouse lethal dose): neurotropic (Nancy strain) and cardiotropic (Woodruff strain) infections. Compounds partnering in a triple combination were selected as enterovirus (EV) replication inhibitors with different mode of action - disoxaril (a VP1 blocker), guanidine.HCl (targeting 2C protein) and oxoglaucine (attacking 3A coding region). The application of this combination by CAA course resulted in around 40 and 60% survival rate in mice infected with Nancy and Woodruff virus, respectively, accompanied by a marked lengthening of the mean survival time (MST). The results obtained are proofs for the prospect of the treatment course by a triple combination through the CAA scheme as an approach interfering the occurrence of drug resistance at EV infections.
27552486	0	13	Effectiveness	T080	C1280519
27552486	21	32	Consecutive	T080	C1707491
27552486	33	44	Alternating	T169	C0332270
27552486	45	66	Administration Course	T079	C0750729
27552486	72	78	Triple	T081	C0205174
27552486	79	88	Antiviral	T121	C1254351
27552486	89	100	Combination	T080	C0205195
27552486	104	132	Coxsackievirus B3 Infections	T047	C2062443
27552486	136	140	Mice	T015	C0025929
27552486	141	157	Anti-enteroviral	T121	C1254351
27552486	158	175	chemotherapeutics	T061	C3665472
27552486	180	188	clinical	T080	C0205210
27552486	189	192	use	T169	C0457083
27552486	197	218	not registered so far	T033	C0243095
27552486	227	233	due to	T169	C0678226
27552486	244	255	development	T169	C1527148
27552486	259	274	drug-resistance	T038	C0013203
27552486	296	306	approaches	T169	C1292724
27552486	310	318	overcome	T052	C2983310
27552486	324	331	problem	T033	C0033213
27552486	339	345	use of	T169	C1524063
27552486	346	354	combined	T080	C0205195
27552486	355	367	chemotherapy	T061	C3665472
27552486	382	393	application	T169	C4048755
27552486	429	434	drugs	T121	C0013227
27552486	439	454	not efficacious	T080	C0205556
27552486	470	481	development	T169	C1527148
27552486	485	504	multiple resistance	T032	C0242640
27552486	524	529	novel	T080	C0205314
27552486	530	538	approach	T169	C1292724
27552486	543	551	combined	T080	C0205195
27552486	567	593	anti-enteroviral compounds	T121	C1254351
27552486	611	649	consecutive alternating administration	T061	C1533734
27552486	651	654	CAA	T061	C1533734
27552486	656	662	course	T079	C0750729
27552486	664	667	CAA	T061	C1533734
27552486	672	678	tested	T169	C0039593
27552486	684	698	in vivo models	T062	C1515657
27552486	702	729	Coxsackievirus B3 infection	T047	C2062443
27552486	733	740	newborn	T008	C0003065
27552486	741	745	mice	T015	C0025929
27552486	761	765	dose	T081	C0178602
27552486	772	777	MLD50	T081	C0023378
27552486	779	800	50% mouse lethal dose	T081	C0023378
27552486	803	814	neurotropic	T047	C0042769
27552486	816	828	Nancy strain	T005	C0042776
27552486	834	875	cardiotropic (Woodruff strain) infections	T047	C0042769
27552486	848	863	Woodruff strain	T005	C0042776
27552486	877	886	Compounds	T103	C1706082
27552486	903	909	triple	T081	C0205174
27552486	910	921	combination	T080	C0205195
27552486	939	950	enterovirus	T005	C0014383
27552486	952	954	EV	T005	C0014383
27552486	956	967	replication	T043	C0042774
27552486	956	978	replication inhibitors	UnknownType	C0042771
27552486	984	993	different	T080	C1705242
27552486	1002	1008	action	T052	C3266814
27552486	1011	1020	disoxaril	T109,T121	C0058467
27552486	1024	1027	VP1	T116,T123	C0042981
27552486	1028	1035	blocker	T121	C1254351
27552486	1038	1051	guanidine.HCl	T109,T121	C0120447
27552486	1053	1062	targeting	T169	C1521840
27552486	1063	1073	2C protein	T116,T126	C0246875
27552486	1079	1090	oxoglaucine	T109,T121	C0673446
27552486	1102	1119	3A coding region)	T082	C1254362
27552486	1125	1136	application	T169	C4048755
27552486	1145	1156	combination	T080	C0205195
27552486	1160	1163	CAA	T061	C1533734
27552486	1164	1170	course	T079	C0750729
27552486	1171	1179	resulted	T169	C1274040
27552486	1201	1214	survival rate	T081	C0038954
27552486	1218	1222	mice	T015	C0025929
27552486	1223	1231	infected	T046	C3714514
27552486	1237	1242	Nancy	T005	C0042776
27552486	1247	1261	Woodruff virus	T005	C0042776
27552486	1320	1338	mean survival time	T081	C0086595
27552486	1340	1343	MST	T081	C0086595
27552486	1350	1357	results	T169	C1274040
27552486	1358	1366	obtained	T169	C1301820
27552486	1371	1377	proofs	T097	C0335256
27552486	1402	1418	treatment course	T079	C0454268
27552486	1424	1430	triple	T081	C0205174
27552486	1431	1442	combination	T080	C0205195
27552486	1455	1458	CAA	T061	C1533734
27552486	1459	1465	scheme	T170	C1519193
27552486	1472	1480	approach	T169	C1292724
27552486	1497	1507	occurrence	T079	C2745955
27552486	1511	1526	drug resistance	T038	C0013203
27552486	1530	1543	EV infections	T047	C0014378